After announcing last month that a late-stage trial for a social anxiety nose spray was unsuccessful, VistaGen is pausing another phase 3 trial to see whether it’s worth continuing.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,